Uday Aditya Sarkar

Dr. Uday Aditya Sarkar


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Biomedicines
Verified
Journal Article
Open access
PDF file
PRPayel Roy
Payel Roy
USUday Aditya Sarkar
Uday Aditya Sarkar
SBSoumen Basak
Soumen Basak
Multiple myeloma(MM), an incurable plasma cell cancer, represents the second most prevalent hematological malignancy. Deregulated activity of the nuclear factor kappaB (NF-κB) family of transcription factors has been implicated in the pathogenesis of multiple myeloma. Tumor microenvironment-derived cytokines and cancer-associated genetic mutations signal through the canonical as well as the non-canonical arms to activate the NF-κB system in myeloma cells. In fact, frequent engagement of both the NF-κB pathways constitutes a distinguishing characteristic of myeloma. In turn, NF-κB signaling promotes proliferation, survival and drug-resistance of myeloma cells. In this review article, we catalog NF-κB activating genetic mutations and microenvironmental cues associated with multiple myeloma. We then describe how the individual canonical and non-canonical pathways transduce signals and contribute towards NF-κB -driven gene-expressions in healthy and malignant cells. Furthermore, we discuss signaling crosstalk between concomitantly triggered NF-κB pathways, and its plausible implication for anomalous NF-κB activation and NF-κB driven pro-survival gene-expressions in multiple myeloma. Finally, we propose that mechanistic understanding of NF-κB deregulations may provide for improved therapeutic and prognostic tools in multiple myeloma.

7 May 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
BCBudhaditya Chatterjee
Budhaditya Chatterjee
PRPayel Roy
Payel Roy
USUday Aditya Sarkar
Uday Aditya Sarkar
MZMingming Zhao
Mingming Zhao
YRYashika Ratra
Yashika Ratra
SBSoumen Basak
Soumen Basak
Tumor necrosis factor (TNF) is a pleiotropic cytokine whose primary physiological function involves coordinating inflammatory and adaptive immune responses. However, uncontrolled TNF signaling causes aberrant inflammation and has been implicated in several human ailments. Therefore, an understanding of the molecular mechanisms underlying dynamical and gene controls of TNF signaling bear significance for human health. As such, TNF engages the canonical nuclear factor kappa B (NF-κB) pathway to activate RelA:p50 heterodimers, which induce expression of specific immune response genes. Brief and chronic TNF stimulation produces transient and long-lasting NF-κB activities, respectively. Negative feedback regulators of the canonical pathway, including IκBα, are thought to ensure transient RelA:p50 responses to short-lived TNF signals. The non-canonical NF-κB pathway mediates RelB activity during immune differentiation involving p100. We uncovered an unexpected role of p100 in TNF signaling. Brief TNF stimulation of p100-deficient cells triggered an additional late NF-κB activity consisting of RelB:p50 heterodimers, which modified the TNF-induced gene-expression program. In p100-deficient cells subjected to brief TNF stimulation, RelB:p50 not only sustained the expression of a subset of RelA-target immune response genes but also activated additional genes that were not normally induced by TNF in WT mouse embryonic fibroblasts (MEFs) and were related to immune differentiation and metabolic processes. Despite this RelB-mediated distinct gene control, however, RelA and RelB bound to mostly overlapping chromatin sites in p100-deficient cells. Repeated TNF pulses strengthened this RelB:p50 activity, which was supported by NF-κB-driven RelB synthesis. Finally, brief TNF stimulation elicited late-acting expressions of NF-κB target pro-survival genes in p100-deficient myeloma cells. In sum, our study suggests that the immune-differentiation regulator p100 enforces specificity of TNF signaling and that varied p100 levels may provide for modifying TNF responses in diverse physiological and pathological settings.

30 October 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NANaqiya Ambareen
Naqiya Ambareen
KGKusumika Gharami
Kusumika Gharami
AMAnanya Mondal
Ananya Mondal
USUday Aditya Sarkar
Uday Aditya Sarkar
SBSubhas C. Biswas
Subhas C. Biswas
Aberrant activation of autophagy contributes to neuronal cell death and plays a pivotal role in the pathogenesis of Alzheimer's disease (AD). To study this further, we assessed autophagy-related (ATG) proteins in 5xFAD mice at different ages and found a progressive inappropriate elevation of autophagic proteins in these mice. We identified a transcriptional coregulator, Sertad1 (SERTA domain-containing protein 1), which plays a necessary role in neuron death, as a key regulator of aberrant autophagy in AD. We found a progressive elevation in Sertad1 levels in 5xFAD mice with age compared with WT mice. Sertad1 knockdown in 5xFAD mice brains lowered levels of ATG proteins and lysosomal proteins, suggesting its role in the regulation of the autophagy-lysosomal pathway. We found that Sertad1 knockdown restored Akt activity, which is inhibited in AD, and blocked the activation of its target, FoxO3a, which is translocated to the nucleus in the absence of active Akt and mediates neuron death by apoptosis and autophagy. Furthermore, we showed that lentivirus-mediated RNAi targeting of Sertad1 in 5xFAD mice led to better performance in behavioral experiments compared with 5xFAD mice treated with nontargeting shRNA, accompanied by significant restoration of synaptic integrity. Overall, our results demonstrated that autophagy is robustly induced with disease progression, but ATG proteins accumulate in the brain because of their impaired clearance; Sertad1 knockdown restored synaptic failure and improved cognition in 5xFAD mice by enhancing clearance of ATG proteins and neuronal survival. Hence, Sertad1 could be an excellent target for therapeutic intervention to combat the multifaceted pathologies of AD.

8 May 2026 in Biology
Verified
Journal Article
Open access
PDF file
USUday Aditya Sarkar
Uday Aditya Sarkar
NANaqiya Ambareen
Naqiya Ambareen
PPParash Prasad
Parash Prasad
MKMohd Kamran
Mohd Kamran
SGSAMPURNA GHOSH
SAMPURNA GHOSH
B cells, an important component of adaptive immunity, play a key role in defense against a variety of infections and diseases including cancer. B cells play a dual role in cancer, contributing to both anti-tumor immunity and tumor progression. Metabolic reprogramming in the TME has a profound impact on B cell dynamics, reshaping their energetic landscape, influencing their differentiation and effector cell functions. These alterations arise from the complex interplay between intrinsic metabolic pathways and extrinsic factors, such as nutrient availability, hypoxic conditions, and tumor-derived signals. In the TME, B cells promote glycolysis over oxidative phosphorylation (OXPHOS) to meet the high energy demands of activation and proliferation. However, this metabolic plasticity is also mimicked by tumors, leading to dysfunctional B cell phenotypes, such as regulatory B cells (Bregs), which suppress anti-tumor immunity. Nutrient deprivation and accumulation of metabolic byproducts, including lactate, further impair B cell-mediated immune responses. This review highlights the complex interaction between B cell metabolism and cancer, emphasizing the effects of altered energetics on B cell function and implications on tumor progression and therapy. Decoding the metabolic vulnerabilities of B cells in the tumor niche can uncover novel therapeutic strategies against cancer.

3 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
USUday Aditya Sarkar
Uday Aditya Sarkar
LKLalit Kumar
Lalit Kumar
SBSoumen Basak
Soumen Basak
Withdrawal Statement: bioRxiv has withdrawn this manuscript because it was posted without the consent of all authors. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author

16 November 2026 in British Journal of Haematology
Verified
Journal Article
Open access
KMKiyomi Mashima
Kiyomi Mashima
SFStacey M. Fernandes
Stacey M. Fernandes
MMMariia Mikhaleva
Mariia Mikhaleva
RARoberta Santos Azevedo
Roberta Santos Azevedo
SMStephen Martindale
Stephen Martindale
JBJennifer R. Brown
Jennifer R. Brown
Summary: We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non‐progressor (NP) group ( N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK ( BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 ( PLCG2 ) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 ( TP53 ), splicing factor 3b subunit 1 ( SF3B1 ), protein phosphatase, Mg 2 + /Mn 2 + dependent 1D ( PPM1D ) and notch receptor 2 ( NOTCH2 ) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen‐activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group ( p = 0.047). These findings suggest that TP53 aberration and 8p‐loss‐associated complex karyotype, as well as several non‐BTK driver mutations, are enriched in BTKi‐resistant patients.